Form 4 for SKYE Skye Bioscience, Inc.
Accepted 2024-02-02 00:00:00 ET · period of report 2024-01-31 · accession 0001209191-24-002649 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-02-02 | 2024-01-31 | SKYE | Schwab Andrew J. | Dir, 10% | A - Grant | $2.31 | +5.21M | 7.94M | +190% | +$12.03M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-31 | A | A | 5,206,074 | $2.31 | 7,943,520 | I By 5AM Ventures VII, L.P. | — | — | (F1) The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |